{"entity":{"id":"idea-lung-small-cell-platform-with-shared-controls-and-subtypes","kind":"idea","name":"Run small-cell lung cancer as one platform with shared controls and subtype stratification","aka":[],"tldr":"Small-cell lung cancer has had two real advances in twenty-five years. It is probably four diseases being tested as one, in separate small trials that each need their own control group.","summary":"Rudin and eighteen colleagues proposed that small-cell lung cancer comprises subtypes defined by ASCL1, NeuroD1, YAP1 and POU2F3 expression, with different therapeutic vulnerabilities. George's genomes explain why conventional targeting failed: the disease is defined by biallelic loss of TP53 and RB1, and losses cannot be inhibited. Progress since has come from elsewhere, from DLL3 as a surface target and from immunotherapy given at lower tumour burden.\n\nThe disease is uncommon enough, and deteriorates fast enough, that individual randomised trials are slow and underpowered, and every one of them spends half its patients on a control arm that is the same in all of them. A platform trial with a shared control, subtype stratification at entry and the ability to drop and add arms is the design the situation calls for, and Lung-MAP has already shown it is operable in squamous non-small-cell disease.","asOf":"2026-09-25","links":[],"tags":["lung-evidence"],"related":["idea-sclc-subtype-directed","trial-modernisation-roadmap","lung-cancer-evidence-roadmap"],"cancers":["lung-cancer","sclc","limited-stage-sclc","extensive-stage-sclc"],"sections":["drug-discovery","immunotherapy"],"technologies":["t-cell-engager","ihc"],"targets":["dll3","tp53","rb1"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["lung-map"],"people":[],"bottlenecks":["b-rare-cancers","b-trial-design","b-undruggable-targets","b-trial-enrolment"],"keyPapers":["paper-rudin-sclc-molecular-subtypes-nat-rev-cancer-2019","paper-george-sclc-genomic-profiles-nature-2015","paper-ahn-dellphi-301-tarlatamab-sclc-nejm-2023","paper-paz-ares-caspian-durvalumab-es-sclc-lancet-2019"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"A subtype-stratified platform trial with a shared control arm detects subtype-specific treatment effects in small-cell lung cancer that parallel-group trials of the same total size cannot, and does so fast enough to matter in a disease with a median survival under a year in extensive stage.","rationale":"Shared controls raise the proportion of patients on experimental arms and cut the sample size needed per comparison. Subtype assignment is measurable on diagnostic material by immunohistochemistry or expression profiling. The candidate arms already exist: DLL3-directed engagers in ASCL1-high disease, PARP and ATR inhibitors where replication stress is high, and checkpoint blockade where inflammation is. Lung-MAP established the operational model in the same tumour site.","test":"A platform protocol in extensive-stage small-cell lung cancer with prospective subtype assignment at registration, a standing platinum-etoposide plus checkpoint inhibitor control, and at least three experimental arms with pre-specified subtype hypotheses and futility rules. Success is measured both on arm-level results and on whether subtype prospectively predicts benefit.","maturity":"preclinical-evidence","actor":"research","cost":"large","horizonYears":7},"route":"/ideas/idea-lung-small-cell-platform-with-shared-controls-and-subtypes/","neighbours":{"idea":[{"id":"idea-sclc-subtype-directed","kind":"idea","name":"Subtype-directed therapy for SCLC (ASCL1 / NEUROD1 / POU2F3 / inflamed)","route":"/ideas/idea-sclc-subtype-directed/"}],"roadmap":[{"id":"lung-cancer-evidence-roadmap","kind":"roadmap","name":"Lung cancer roadmap: from Doll and Hill and the naming of tobacco, through the cytotoxic plateau, computed tomography screening, EGFR and ALK, immunotherapy by PD-L1, the perioperative trials and PACIFIC, to DLL3 in small-cell disease and a 2032 registry watch","route":"/roadmaps/lung-cancer-evidence-roadmap/"},{"id":"trial-modernisation-roadmap","kind":"roadmap","name":"Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on","route":"/roadmaps/trial-modernisation-roadmap/"}],"cancer":[{"id":"extensive-stage-sclc","kind":"cancer","name":"Extensive-stage small-cell lung cancer","route":"/cancers/extensive-stage-sclc/"},{"id":"limited-stage-sclc","kind":"cancer","name":"Limited-stage small-cell lung cancer","route":"/cancers/limited-stage-sclc/"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"section":[{"id":"drug-discovery","kind":"section","name":"Drug Discovery Platforms","route":"/fronts/drug-discovery/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"term":[{"id":"ihc","kind":"term","name":"Immunohistochemistry (IHC)","route":"/terms/ihc/"}],"target":[{"id":"dll3","kind":"target","name":"DLL3","route":"/targets/dll3/"},{"id":"rb1","kind":"target","name":"RB1","route":"/targets/rb1/"},{"id":"tp53","kind":"target","name":"TP53","route":"/targets/tp53/"}],"trial":[{"id":"lung-map","kind":"trial","name":"Lung-MAP (SWOG S1400 and S1900)","route":"/trials/lung-map/"}],"bottleneck":[{"id":"b-rare-cancers","kind":"bottleneck","name":"Rare and paediatric cancers without markets","route":"/bottlenecks/b-rare-cancers/"},{"id":"b-undruggable-targets","kind":"bottleneck","name":"The undruggable drivers","route":"/bottlenecks/b-undruggable-targets/"},{"id":"b-trial-design","kind":"bottleneck","name":"Trial design, endpoints and cost","route":"/bottlenecks/b-trial-design/"},{"id":"b-trial-enrolment","kind":"bottleneck","name":"Trials enrol too few, too slowly","route":"/bottlenecks/b-trial-enrolment/"}],"paper":[{"id":"paper-george-sclc-genomic-profiles-nature-2015","kind":"paper","name":"Comprehensive genomic profiles of small cell lung cancer","route":"/key-papers/paper-george-sclc-genomic-profiles-nature-2015/"},{"id":"paper-paz-ares-caspian-durvalumab-es-sclc-lancet-2019","kind":"paper","name":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN)","route":"/key-papers/paper-paz-ares-caspian-durvalumab-es-sclc-lancet-2019/"},{"id":"paper-rudin-sclc-molecular-subtypes-nat-rev-cancer-2019","kind":"paper","name":"Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data","route":"/key-papers/paper-rudin-sclc-molecular-subtypes-nat-rev-cancer-2019/"},{"id":"paper-ahn-dellphi-301-tarlatamab-sclc-nejm-2023","kind":"paper","name":"Tarlatamab for patients with previously treated small-cell lung cancer","route":"/key-papers/paper-ahn-dellphi-301-tarlatamab-sclc-nejm-2023/"}]}}